Our technology enables the production of a complete autologous engineered tissue composed of matrix and cells derived from patients’ own tissues. The scaffold is a thermo-responsive hydrogel, prepared by decellularization of patient’s omentum biopsy, while the induced pluripotent stem cells (iPSCs) are re-programmed from patient’s mature cells. Ex-vivo differentiation of iPSCs within the thermo-responsive hydrogel leads to the generation of a functional mature tissue.
Our proprietary technology platform is the essence of engineering autologous neural implants. Differentiated iPSCs derived neural cells within extra cellular matrix (ECM) creates functional spinal cord implants that can bridge and regenerate injured spinal cord tissue. A first in human phase I/IIa clinical trial is scheduled for 2024.
In 2019, Matricelf licensed the technology that enabled printing the first [functioning] 3D human heart from cells and matrix derived from a human omentum biopsy from Tel Aviv University.
Matricelf’s novel regenerative medicine platform aims to cure a range of medical conditions including Spinal Cord Injuries (SCI), Age-related Macular Degeneration (AMD), Parkinson’s Disease, Myocardial Infarction et al.